AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03581357 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Mindfulness Meditation
Description: It is hypothesized that participants who are randomized in the app condition will have significantly less anxiety, pain, fatigue, and sleep disturbance than their counterparts in the control condition.
Study NCT03041220 — intervention group
Intervention type: PROCEDURE
Intervention: cesarean section
Description: obese patients (BMI of 30 or greater) who have had a cesarean section
Study NCT03581357 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Coach
Description: It is hypothesized that participants who are randomized into treatment condition will have significantly less CIPN, anxiety, and fatigue, and improved anxiety, in comparison to their counterparts in the wait-list control condition.
Study NCT02447185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection.~All subjects in Ranibizumab group will get Ranibizumab 0.2 mg/0.02 ml intravitreal injection just after the operation.
Study NCT02447185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: A week before 25-gauge vitrectomy, all subjects in TA group will receive Triamcinolone Acetonide 4mg/0.1ml intravitreal injection.~During operation all subjects in Ranibizumab group and in TA group will be injected Triamcinolone Acetonide 4 mg/0.1ml.~All subjects in TA group will get Triamcinolone Acetonide 1mg/0.025 ml intravitreal injection just after the operation.
Study NCT02447185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: A week before 25-gauge vitrectomy, all subjects in TA group will receive Triamcinolone Acetonide 4mg/0.1ml intravitreal injection.~During operation all subjects in Ranibizumab group and in TA group will be injected Triamcinolone Acetonide 4 mg/0.1ml.~All subjects in TA group will get Triamcinolone Acetonide 1mg/0.025 ml intravitreal injection just after the operation.
Study NCT03055156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High rebound mattress toppers
Description: Patients will sleep on this mattress topper during their diagnostic sleep study.
Study NCT02647671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aquamin®
Description: 90 days of Aquamin
Study NCT02647671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: 90 days of Calcium Carbonate
Study NCT03133117 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Functional Magnetic Resonance Imaging (fMRI)
Study NCT01280617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Thymoglobulin 1.25mg/kg dose
Study NCT02647671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 90 days of placebo
Study NCT01280617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin 0.75mg/kg dose
Description: Thymoglobulin
Study NCT03346993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride 5 MG/ML
Description: Ultrasound guided infraclavicular brachial plexus block with warmed bupivacaine
Study NCT02018120 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft
Study NCT02018120 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: platelet rich fibrin
Study NCT03663543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated Estrogen
Description: Dosing of conjugated estrogen will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.
Study NCT03663543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Dosing of normal saline will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.
Study NCT03741062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J. Morita AdvErl Evo Er:YAG laser
Description: Er:YAG laser perimeters:~Energy = 80 mJ Pulse Rate = 25 Hz Duration = 30 s
Study NCT03741062 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Sham treatment with laser unit turned off
Study NCT02121431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Triple P--Positive Parenting Program
Description: The Triple P--Positive Parenting Program (Triple P), which has an extensive evidence base, is grounded in a common set of core principles of positive parenting and draws on a broad menu of parenting strategies. A key provision of Triple P is that parents are the decision-makers about program goals and selection/implementation of specific parenting strategies consistent with their preferences and values.
Study NCT02121431 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Triple P--Positive Parenting Program
Description: The Triple P--Positive Parenting Program (Triple P), which has an extensive evidence base, is grounded in a common set of core principles of positive parenting and draws on a broad menu of parenting strategies. A key provision of Triple P is that parents are the decision-makers about program goals and selection/implementation of specific parenting strategies consistent with their preferences and values.
Study NCT03636984 — intervention group
Intervention type: DRUG
Intervention: recombinant TNF-α receptor: IgG Fc fusion protein
Description: 50mg weekly
Study NCT01814631 — intervention group
Intervention type: OTHER
Intervention: image quality and resolution
Description: Image quality and resolution will be viewed using Aloka processor
Study NCT01814631 — intervention group
Intervention type: OTHER
Intervention: image quality and resolution
Description: image quality and resolution will be viewed on the EU-me2
Study NCT01797731 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital hand-held surgical navigation system
Description: Digital hand-held surgical navigation system used for tibial component placement in total knee arthroplasty
Study NCT01797731 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional tibial extramedullary alignment system
Description: This is the standard of care for total knee arthroplasty.
Study NCT04167982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid photodynamic therapy
Description: Aminolevulinic acid photodynamic therapy
Study NCT04167982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral conventional-dose isotretinoin
Description: Conventional-dose isotretinoin
Study NCT04167982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral low-dose isotretinoin
Description: low-dose isotretinoin
Study NCT03609879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu Perfect ACE
Description: patient with a fitted cervical collar (Ambu Perfect ACE) established by an experienced instructor. Cervical collar set up for 20 minutes
Study NCT03609879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philly One-Peace Collar
Description: patient with a fitted cervical collar (Philly One-Peace Collar) established by an experienced instructor. Cervical collar set up for 20 minutes
Study NCT03609879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Necloc Collar
Description: patient with a fitted cervical collar (Neclock Collar) established by an experienced instructor. Cervical collar set up for 20 minutes
Study NCT03609879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NexSplit Plus
Description: patient with a fitted cervical collar (NexSplit Plus) established by an experienced instructor. Cervical collar set up for 20 minutes
Study NCT03697538 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve Block for pain control post-revision total knee arthroplasty
Description: A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
Study NCT03697538 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Block for pain control post-revision total knee arthroplasty
Description: A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
Study NCT03666403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIV rate: 0/min
Description: A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
Study NCT03666403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIV rate: 10-20/min
Description: A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
Study NCT03666403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIV rate: 5-10/min
Description: A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
Study NCT01340417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurements of melatonin levels in urine, blood, milk.
Description: Measurements of melatonin levels in urine, blood, milk.
Study NCT01352611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: baclofen, intrathecal
Description: Patients will undergo a standard intrathecal baclofen trial procedure. This procedure consists of a single injection of 50 micrograms of baclofen between the 4th and 5th lumbar vertebrae into the spinal fluid.
Study NCT04441645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: acupressure once per day, five times per week, a total of 12 weeks
Study NCT03617627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management intervention
Description: Self-management intervention will include presentation and discussion of various topics regarding chronic pain mechanisms and pain self-monitoring. The intervention will also incorporate a task-oriented approach focused on relevant activities in order to acquire coping skills.
Study NCT04121117 — intervention group
Intervention type: OTHER
Intervention: Chronic obstructive pulmonary disease screening
Description: To verify the tobacco withdrawal, the patients will make a cooximetry.~For the detection of a possible obstructive pattern a measurement of the ventilatory capacity will be make using the COPD-6 device and for the confirmation of COPD diagnosis and the assesment of the airflow obstruction severity a spirometry will be make.~The patients will also complete the COPD-PS questionnaire.
Study NCT02039752 — intervention group
Intervention type: OTHER
Intervention: Treatment
Study NCT01037582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NN9924 (oral)
Description: Subjects will be randomized to receive a single dose of NN9924, at escalating dose levels. Progression to next dose will be based on safety evaluation.
Study NCT01037582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will receive a single dose of placebo as a comparator to NN9924, at all dose levels.
Study NCT01037582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NN9924 (oral)
Description: Subjects will be randomized to receive a single dose of NN9924 in one of three different concentrations. The dose will be selected based on the results of part 1.
Study NCT01037582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will be randomized to receive a single dose of placebo.
Study NCT01037582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NN9924 (s.c.)
Description: As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit
Study NCT01037582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NN9924 (i.v.)
Description: As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit.
Study NCT00802282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: psilocybin
Description: dose manipulation as described in the protocol and to which volunteers are blinded
Study NCT00802282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensity of support for spiritual practice
Description: Volunteers will be assigned to standard or high support, as described in the protocol
Study NCT00802282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Number of sessions
Description: Volunteers will be assigned to either 2 or 3 sessions, as described in the protocol
Study NCT01793818 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Tat Oyi
Description: Three injections in the arm
Study NCT01793818 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tat Oyi
Description: Three injections in the arm
Study NCT01991288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SNB Saphenous Nerve Block
Description: Patients in group SNB received an ultrasound guided SNB (a sub sartorial approach) by a single operator with 10 mls 0.5% bupivacaine. At the end of surgery periarticular knee infiltration of 30 mls 0.5% levobupivacaine + 70 mls 0.9% saline + 0.5 mg adrenaline was performed in a staged fashion by the surgeon, beginning with infiltration of the deep structures on tibial surface at 1mm depth around all exposed tissues, medial and lateral collateral ligament origin, all cut surfaces of extensor mechanism, all cut surface of skin and subcutaneous tissue
Study NCT01991288 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NSNB Non Saphenous Nerve Block
Description: All patients at the end of surgery received periarticular knee infiltration of 30 mls 0.5% levobupivacaine + 70 mls 0.9% saline + 0.5 mg adrenaline, in a staged fashion by the surgeon, beginning with infiltration of the deep structures on tibial surface at 1mm depth around all exposed tissues, medial and lateral collateral ligament origin, all cut surfaces of extensor mechanism, all cut surface of skin and subcutaneous tissue
Study NCT00799916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resuscitation (Voluven)
Description: Resuscitation aimed at venous oxygen saturation higher than 70%
Study NCT00799916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resuscitation (Saline)
Description: Resuscitation aimed at venous oxygen saturation higher than 70%
Study NCT01355354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: oral tablets, 0.25mg bd on Day 1 and 0.25 Once daily from Day 2 to 15
Study NCT01355354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: oral tablets, 100mg (2 X 50mg) bd from Day 9 - 15
Study NCT01932099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement
Description: Direct Flow Medical Transcatheter Aortic Valve System is indicated for use in aortic stenosis for patients at extreme surgical risk for aortic valve replacement.
Study NCT04600024 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound guided diagnostic injection
Description: 4 cc lidocaine %2 injection into the piriformis muscle was performed for the diagnosis of piriformis syndrome. It was performed by the ultrasound-guidance to increase the accuracy of the injection.
Study NCT00685802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol 50 mg Tablets
Description: Cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours
Study NCT00685802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol (Pletal®) 50 mg Tablets
Description: Cilostazol (Pletal® Tablets, 2 x 50mg) administered after an overnight fast of at least 10 hours.
Study NCT01443559 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Xenogenic cornea
Description: lamellar acellular xenogenic corneas were sterilised by radiation
Study NCT01443559 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: homogenic cornea
Description: homogenic corneas were sterilised by radiation
Study NCT02332408 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cybernetic microradiosurgery
Description: Cybernetic microradiosurgery (6MV) using tracking to TD 25Gy given in five fraction (5Gy p fr) two or three days a week, during 2 weeks
Study NCT02332408 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiotherapy
Description: Conventionally fractionated linac based external beam radiation therapy - EBRT, (conformal or dynamic) to the TD of 36 Gy, in 2.0 Gy per fraction 5 days a week over the period of 3.5 weeks)
Study NCT00751738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azimilide dihydrochloride
Description: oral, once daily until sponsor stopped the study
Study NCT03458247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone acetate standard dose
Description: 1000 mg/day
Study NCT03505983 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESR Prosthetic Foot First
Description: Subjects will start with an ESR foot first for 1 week, then will complete an additional week with an articulating ESR foot and a powered foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
Study NCT03609879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NECKLITE
Description: patient with a fitted cervical collar (NECKLITE) established by an experienced instructor. Cervical collar set up for 20 minutes
Study NCT02147470 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Definity ultrasound contrast agent
Description: All subjects will undergo CEUS of the kidney at baseline to measure renal blood flow. This procedure will be repeated after volume expansion and if indicated, once again after treatment with albumin, midodrine and octreotide.
Study NCT00129272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion-SR
Description: 150mg tablets taken orally twice daily for 9 weeks.
Study NCT00129272 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (to Buproion-SR) twice daily for 9 weeks.
Study NCT03505983 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Articulating ESR Prosthetic Foot First
Description: Subjects will start with an articulating ESR foot first for 1 week, then will complete an additional week with an articulating ESR foot and a powered foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
Study NCT03505983 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Powered Prosthetic Foot First
Description: Subjects will start with a powered prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR foot and an ESR foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
Study NCT03358693 — intervention group
Intervention type: DRUG
Intervention: Ustekinumab
Description: Subject receives Ustekinumab open-label as per guidelines
Study NCT03358693 — intervention group
Intervention type: DRUG
Intervention: Infliximab
Description: Subject receives Infliximab open-label as per guidelines
Study NCT03358693 — intervention group
Intervention type: DRUG
Intervention: Secukinumab
Description: Subject receives Secukinumab open-label as per guidelines
Study NCT03358693 — intervention group
Intervention type: DRUG
Intervention: Dupilumab
Description: Subject receives Dupilumab open-label as per guidelines